Home › Funds › GREAT POINT PARTNERS LLC › EPRX

GREAT POINT PARTNERS LLC position in EPRX

EUPRAXIA PHARMACEUTICALS INC · Health Care

GREAT POINT PARTNERS LLC reported holding 1,200,000 shares of EPRX (EUPRAXIA PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$7.9M, representing 1.67% of its reported portfolio and ranking #22 among its reported holdings. GREAT POINT PARTNERS LLC has disclosed EPRX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

Latest position (Q2 2026)1.20M sh
Reported value held$7.93M
Portfolio Weight1.67%
First reportedQ3 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How GREAT POINT PARTNERS LLC's EPRX position evolved

GREAT POINT PARTNERS LLC first disclosed a stake in EPRX in Q3 2025 at 1,200,000 shares (US$7.1M). The position peaked in Q4 2025 at 1,200,000 shares, worth US$9.1M. Across 4 filings, GREAT POINT PARTNERS LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 1,200,000 shares valued at US$7.9M.

Quarter by quarter

QuarterSharesValueChange
Q3 2025 1.20M $7.08M New
Q4 2025 1.20M $9.06M Hold
Q1 2026 1.20M $8.69M Hold
Q2 2026 1.20M $7.93M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About EPRX and 13F data

EPRX (EUPRAXIA PHARMACEUTICALS INC) is a Health Care company. 69 other funds we track also report a position in EPRX — the largest reported positions include Vivo Capital, LLC (US$8.9M), PFM Health Sciences, LP (US$8.0M), Ikarian Capital, LLC (US$5.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding EPRX

All EPRX fund holders →

FAQ

How long has GREAT POINT PARTNERS LLC held EPRX?

GREAT POINT PARTNERS LLC has disclosed EPRX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

What is GREAT POINT PARTNERS LLC's current position in EPRX?

As of Q2 2026, GREAT POINT PARTNERS LLC holds 1.20M shares of EPRX (EUPRAXIA PHARMACEUTICALS INC), valued at $7.93M, representing 1.67% of its reported portfolio and ranking #22.

Has GREAT POINT PARTNERS LLC been buying or selling EPRX?

In the latest 13F filing (Q2 2026), GREAT POINT PARTNERS LLC held unchanged its position in EPRX. The position peaked in Q4 2025 at 1.20M shares.

Which other funds hold EPRX?

Other major institutional holders of EPRX include Vivo Capital, LLC, PFM Health Sciences, LP, Ikarian Capital, LLC, among 69 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.